Upload
sine
View
26
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Key Strategies for Improving Use of Existing and New Antibiotics -the European Experience. Otto Cars Professor Inf. Diseases, Uppsala University, Sweden Chairman, ReAct – Action on Antibiotic Resistance . www.reactgroup.org. What is the European Union?. 27 Member States - PowerPoint PPT Presentation
Citation preview
Key Strategies for Improving Use of Existing and New Antibiotics
-the European Experience
Otto Cars
Professor Inf. Diseases, Uppsala University, Sweden
Chairman, ReAct – Action on Antibiotic Resistance www.reactgroup.org
What is the European Union?• 27 Member States
• 23 official languages
• > 500 million inhabitants(per country: 416,333 – 81.7 million)
• €25,100 GDP/capita (per country : 10,400 – 69,300)
• A patchwork of cultures!
1 € = 0.88 £ = 1.43 US$
No data
No awarenessNo priority
No funding
Antibiotic Resistance - the vicious circle
Key Strategies for Improving Use of Existing and New Antibiotics -the European Experience
Data
Awareness
National coordination
Interventions
Klebsiella pneumoniae : proportion of multidrug*-resistant invasive isolates resistant, 2010
Source: EARS-Net, 2011.
*Resistant tothird-generationcephalosporins, fluoroquinolones and aminoglycosides
European Antibiotic Resistance Surveillance: EARS-net
Source: European Surveillance of Antimicrobial Consumption (ESAC).
Outpatient antibiotic (J01) use, by antibiotic class according to ATC classification, 2009
Cyprus and Lithuania: total use, i.e. including inpatients.Spain: reimbursement data, i.e. not including over-the-counter sales without a prescription,
Gre
ece
Cypr
us*
Fran
ce
Italy
Luxe
mbo
urg
Belg
ium
Slov
akia
Pola
nd
Portu
gal
Mal
ta
Irela
nd
Lith
uani
a*
Spai
n**
Icel
and
Bulg
aria
Czec
h Re
pu...
Finl
and
Unite
d Ki
n...
Hung
ary
Denm
ark
Aust
ria
Norw
ay
Ger
man
y
Slov
enia
Swed
en
Neth
erla
nds
Esto
nia
Latv
ia
0
5
10
15
20
25
30
35
40Other J01 classes
Sulfonamides and trimethoprim (J01E)
Quinolones (J01M)
Macrolides, lincosamides and streptogramins (J01F)
Tetracyclines (J01A)
Cephalosporins and other beta-lactams (J01D)
Penicillins (J01C)
DDD
per 1
000
inha
bita
nts
and
per d
ay
U
K
Czec
h Re
p.
Source: ESAC, 2011.
European Surveillance of Antibiotic Consumption (ESAC)
Human burden
Economic burden
Burden of multidrug-resistant (MDR) bacteria in the EU, Iceland and Norway
Infections (6 most frequent MDR bacteria, 4 main types of infection) approx. 400,000 / yearAttributable deaths approx. 25,000 / yearExtra hospital days approx. 2.5 million / year
Extra in-hospital costs approx. € 900 million / year Productivity losses approx. € 600 million / year
SoLimitation: these are underestimatesSource: ECDC, 2009.In:http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time to_React.pdf
18 November 2011
http://antibiotic.ecdc.europa.eu
Images from national campaigns on prudent use of antibiotics
Council Recommendation on the prudent use of antimicrobial agents, 2001
Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC)
Photo: Stuart Chalmers, CC-BY
Implementation of National Intersectoral Coordination Mechanisms on AMR
Adapted from: European Commission, Directorate - General Health and Consumers, 2010. http://ec.europa.eu/health/antimicrobial_resistance/key_documents/index_en.htm
As of 2008, 18 EU Member States and Norway had implemented an Intersectoral Coordination Mechanism
19871988
19891990
19911992
19931994
19951996
19971998
19992000
20012002
20032004
20052006
20072008
20090
200
400
600
800
1000
1200
1400
0 - 45-1415 - 6465 - 99
Rece
pt/
1000
invå
nare
och
år
Antibiotic presciptions/1000 in different age groups in Sweden
http://www.ameli.fr/fileadmin/user_upload/documents/DP_Antibiotiques_10-01-2008.pdf
Antibiotic Use by Age Group in France
0
10
20
30
40
50
60
% R
esis
tant
0
20
40
60
1990
2005
% R
esist
ant
S. pneumoniae, penicillin-non susceptible S. pneumoniae, erythomycin-resistant S. pyogenes, erythromycin-resistant
France Belgium
Source: French Nat. Ref. Ctr. for S. pneumoniae (Courtesy: E. Varon, L. Gutmann & B. Schlemmer) & Belgian Nat. Ref. Ctrs. for S. pneumoniae and for S. pyogenes (Courtesy: BAPCOC, H. Goossens)
Decreases in antimicrobial resistance following national media campaigns
Cathegory• Community aqcuired?
• Hospital acquired?
• Surgical prophylaxis?
Specific indication• Septicemia?
• Pneumonia?
• Wound infection?
• UTI?
Changing prescribing pattern in pneumonia through real time feedback (DDD defined daily dosages)
0500
100015002000250030003500400045005000
2007-Q1
2007-Q2
2007-Q3
2007-Q4
2008-Q1
2008-Q2
2008-Q3
2008-Q4
2009-Q1
2009-Q2
2009-Q3
2009-Q4
Cefuroxim+cefotaxim Penicillin G
Implementation of SAI
A user friendly system coupling prescriptions to
diagnosis in hospitals
We are facing a public health threat
AntibioticResistance
DrugDevelopment
MorbidityMortality
Costs
Is there a need to change the present market system ?
YES !
Innovative Incentives for Effective Antibacterials
A conference during the Swedish Presidency of the EU 2009 focusing on the need to reinvigorate research and development of new antibiotics
GovernmentsAcademiaPharmacuetical and biotech industryCivil society
Justifies intervention from the public sector
Urgent need for new antibiotics
Market failure
Impending health crisis
High health and economic burden from resistance
New collaborative models needed
Urgent need for new antibiotics
The overall innovative capacity is low
There are major scientific challenges
Who is going to do the work?Big Pharma? Small pharma? Academia?
But we cannot keep (mis)using them the way we have for the last 70 years!
Marketing and use needs to be restricted De-linking return of investment from sales !
We need a new business logic!
Urgent need for new antibiotics
From the EU Commission Action Plan on Antimicrobial Resistance launched TODAY in Brussels
Adapted from Källander, 2005
Access Excess
A new business model must be built on the global needsand secure access and affordability as well as rational use